JACC. Cardiovascular interventions · 2026
Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta-Analysis of Randomized Trials.
СтатьяМетаанализСистематический обзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Galli Mattia, Vinciguerra Mattia, Laudani Claudio, Occhipinti Giovanni, D'Amario Domenico, Iaconelli Antonio, Franchi Francesco, Greco Ernesto, Frati Giacomo, Sciarretta Sebastiano, Capodanno Davide, Gorog Diana A, Lopes Renato D, Gibson C Michael, Mehran Roxana, Angiolillo Dominick J
Аннотация
BACKGROUND: The optimal antithrombotic therapy for patients with chronic coronary syndrome (CCS) who also require long-term oral anticoagulation (OAC) remains uncertain.
OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of OAC monotherapy compared with OAC plus single antiplatelet therapy (SAPT) in CCS patients with an indication for long-term anticoagulation.
METHODS: Randomized trials comparing OAC monotherapy with OAC plus SAPT in patients with CCS and indication for long-term OAC from the PubMed, Cochrane Central, Web of Science, and Scopus databases up to November 10, 2025 were included in this systematic review and meta-analysis. HRs and 95% CIs were estimated through a random-effects meta-analytical framework. The primary efficacy endpoint was trial-defined major adverse cardiovascular events, and the primary safety endpoint was any bleeding.
RESULTS: Six trials comprising 5,924 patients were included. The median follow-up duration was 2.3 years (Q1-Q3: 1.3-2.9 years), the median CHA2DS2-VASc score was 4.2 (Q1-Q3: 4.0-4.6), and the median time from revascularization to randomization 3.8 years (Q1-Q3: 3.2-4.4 years). Compared with OAC plus SAPT, OAC monotherapy showed similar rates of major adverse cardiovascular events (6.8% vs 8.2%; HR: 0.85; 95% CI: 0.64-1.09; I2 =23%) and reduced risk of bleeding (8.9% vs 16.1%; HR: 0.49; 95% CI: 0.44-0.55; I2 =8%). OAC monotherapy also reduced cardiovascular death (HR: 0.69; 95% CI: 0.48-0.97; I2 =0%), net adverse clinical events (HR: 0.60; 95% CI: 0.47-0.78; I2 =66%), and major bleeding (HR: 0.46; 95% CI: 0.32-0.66; I2 =47%) compared with OAC plus SAPT. There were no significant differences in myocardial infarction, stroke, or all-cause mortality.
CONCLUSIONS: In patients with CCS requiring long-term OAC, OAC monotherapy was associated with reduced bleeding, cardiovascular death, and net adverse clinical events compared with OAC plus SAPT. (Anticoagulation Alone vs Anticoagulation Plus Antiplatelet Therapy in Atrial Fibrillation With Stable Coronary Disease: A Meta-Analysis of Randomized Trials; CRD420251174643).
OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of OAC monotherapy compared with OAC plus single antiplatelet therapy (SAPT) in CCS patients with an indication for long-term anticoagulation.
METHODS: Randomized trials comparing OAC monotherapy with OAC plus SAPT in patients with CCS and indication for long-term OAC from the PubMed, Cochrane Central, Web of Science, and Scopus databases up to November 10, 2025 were included in this systematic review and meta-analysis. HRs and 95% CIs were estimated through a random-effects meta-analytical framework. The primary efficacy endpoint was trial-defined major adverse cardiovascular events, and the primary safety endpoint was any bleeding.
RESULTS: Six trials comprising 5,924 patients were included. The median follow-up duration was 2.3 years (Q1-Q3: 1.3-2.9 years), the median CHA2DS2-VASc score was 4.2 (Q1-Q3: 4.0-4.6), and the median time from revascularization to randomization 3.8 years (Q1-Q3: 3.2-4.4 years). Compared with OAC plus SAPT, OAC monotherapy showed similar rates of major adverse cardiovascular events (6.8% vs 8.2%; HR: 0.85; 95% CI: 0.64-1.09; I2 =23%) and reduced risk of bleeding (8.9% vs 16.1%; HR: 0.49; 95% CI: 0.44-0.55; I2 =8%). OAC monotherapy also reduced cardiovascular death (HR: 0.69; 95% CI: 0.48-0.97; I2 =0%), net adverse clinical events (HR: 0.60; 95% CI: 0.47-0.78; I2 =66%), and major bleeding (HR: 0.46; 95% CI: 0.32-0.66; I2 =47%) compared with OAC plus SAPT. There were no significant differences in myocardial infarction, stroke, or all-cause mortality.
CONCLUSIONS: In patients with CCS requiring long-term OAC, OAC monotherapy was associated with reduced bleeding, cardiovascular death, and net adverse clinical events compared with OAC plus SAPT. (Anticoagulation Alone vs Anticoagulation Plus Antiplatelet Therapy in Atrial Fibrillation With Stable Coronary Disease: A Meta-Analysis of Randomized Trials; CRD420251174643).